Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Larimar Therapeutics (Nasdaq: LRMR) will present at the 44th Annual J.P.
Rhea-AI Summary
Larimar Therapeutics (Nasdaq: LRMR) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12–15, 2026. Management presentation is scheduled for Wednesday, January 14, 2026, 9:00–9:40 AM PST, and the team will participate in 1x1 investor meetings during the conference.
A live webcast will be available at the conference portal and a replay will be posted on Larimar’s Events and Presentations page for 30 days after the presentation.
Positive
- None.
Negative
- None.
Details
News Market Reaction – LRMR
On Dec 18, the day this news came out, LRMR closed 0.87% below the previous close.
Data tracked by StockTitan Argus for the Dec 18 session.
Key Figures
- Conference dates
- January 12–15, 2026
- 44th Annual J.P. Morgan Healthcare Conference
- Presentation date
- Wednesday, January 14, 2026
- Larimar company presentation
- Presentation time
- 9:00–9:40 AM PST
- Scheduled J.P. Morgan conference slot
- Replay availability
- 30 days
- Duration replay remains on Larimar’s website
Historical Context
-
Strong FA data and cash runway update paired with Q3 financials.
-
Positive FA efficacy signals offset by seven anaphylaxis events and protocol changes.
-
Scheduled call to discuss nomlabofusp development and open‑label study data.
-
Robust cash position, BLA timing, and program progress including FDA feedback.
-
Underwritten stock offering to fund nomlabofusp and corporate purposes.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BALA CYNWYD, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in 1x1 investor meetings at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12 – 15, 2026.
Details on the presentation can be found below.
Date: Wednesday, January 14, 2026
Time: 9:00 – 9:40 AM PST
Following the conclusion of the presentation, a replay will be available for 30 days on the “Events and Presentations” page of Larimar’s website.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.